Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?

<i>Introduction</i>: Studies on neoadjuvant treatment have been actively conducted in patients with resectable pancreatic cancer. However, neoadjuvant treatment effectiveness, especially in clinical T1 stage patients, still needs to be determined. We comparatively evaluated the oncologic...

Full description

Bibliographic Details
Main Authors:	Hyung Sun Kim, Kenji Nakagawa, Takahiro Akahori, Kota Nakamura, Tadataka Takagi, Masayuki Sho, Joon Seong Park, Dong Sup Yoon
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	Journal of Clinical Medicine
Subjects:	neoadjuvant therapy pancreatic neoplasms gemcitabine
Online Access:	https://www.mdpi.com/2077-0383/10/4/873

Similar Items

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
by: Chenqi Wang, et al.
Published: (2022-06-01)

Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS
by: Taku Aoki, et al.
Published: (2024-02-01)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
by: Tadataka Takagi, et al.
Published: (2023-04-01)

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
by: Daisaku Yamada, et al.
Published: (2021-08-01)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
by: Yi Tat Tong, et al.
Published: (2023-05-01)

Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma
by: Tadataka Takagi, et al.
Published: (2023-03-01)

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
by: Jiro Kimura, et al.
Published: (2022-05-01)

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
by: Emerson Y. Chen, et al.
Published: (2023-06-01)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
by: Aurélien Lambert, et al.
Published: (2021-09-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement
by: Takahiro Akahori, et al.
Published: (2024-01-01)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
by: Jerome Raffenne, et al.
Published: (2019-11-01)

Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism
by: Rina Fujiwara-Tani, et al.
Published: (2022-07-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
by: Tianpeng Zhang, et al.
Published: (2023-12-01)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
by: Bathiya Ratnayake, et al.
Published: (2020-07-01)

Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
by: Alessandro Coppola, et al.
Published: (2023-05-01)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
by: Ella Rimmer, et al.
Published: (2022-07-01)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
by: Sumit Sahni, et al.
Published: (2023-09-01)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
by: Victor Mortier, et al.
Published: (2022-12-01)

Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma
by: Kai Tai Derek Yeung, et al.
Published: (2024-01-01)

The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
by: Ling-Wei Hii, et al.
Published: (2019-09-01)

Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma
by: Wade Christopher, et al.
Published: (2022-12-01)

Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma
by: Manoj Amrutkar, et al.
Published: (2023-01-01)

Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis
by: Lanpeng Lu, et al.
Published: (2023-11-01)

The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma
by: Masaru Matsumura, et al.
Published: (2023-03-01)

A case of complete resection of prostate stromal sarcoma after neoadjuvant chemotherapy
by: Naoto Hodotsuka, et al.
Published: (2023-07-01)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
by: Liu T, et al.
Published: (2018-11-01)

Quimioterapia neoadjuvante torna ressecável carcinoma de cabeça de pâncreas
by: Marco Antônio Cezário de Melo, et al.

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
by: Feng Shao, et al.
Published: (2018-06-01)

Targeting BPTF Sensitizes Pancreatic Ductal Adenocarcinoma to Chemotherapy by Repressing ABC-Transporters and Impairing Multidrug Resistance (MDR)
by: Raúl Muñoz Velasco, et al.
Published: (2022-03-01)

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma
by: Anish J. Jain, et al.
Published: (2023-08-01)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Use of Intraoperative Radiotherapy in Pancreatic Cancer After Neoadjuvant Chemoradiotherapy: First National Application
by: Emin KÖSE, et al.
Published: (2016-12-01)

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01)

Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1)
by: Suizhi Gao, et al.
Published: (2019-03-01)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
by: Tomas Koltai, et al.
Published: (2022-05-01)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
by: Marie-Lucie Racu, et al.
Published: (2023-07-01)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
by: Hui Tang, et al.
Published: (2022-12-01)

Synchronous Primary Renal Cell Carcinoma and Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review
by: Tarik Mahfoud, et al.
Published: (2017-11-01)